Venlafaxine reverses chronic fatigue-induced behavioral, biochemical and neurochemical alterations in mice

Pharmacology Biochemistry and Behavior

Volumn 89, Issue 4, 2008, Pages 563-571

  Dhir, Ashish ^a   Kulkarni, S K ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Behavioral alterations; Chronic fatigue; Neurotransmitters; Oxidative stress; Venlafaxine

Indexed keywords

ASCORBIC ACID; BIOGENIC AMINE; BRAIN ENZYME; DOPAMINE; GLUTATHIONE; LIPID; MYELOPEROXIDASE; NEUROTRANSMITTER; NITRITE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADRENAL GLAND; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR CHANGE; BRAIN HOMOGENATE; CHEMICAL ANALYSIS; CHRONIC FATIGUE SYNDROME; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; FORCED SWIMMING TEST; HYPERALGESIA; IMMOBILIZATION; LIPID PEROXIDATION; LOCOMOTION; MALE; MOUSE; MUSCLE CONTRACTION; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CYCLOHEXANOLS; DISEASE MODELS, ANIMAL; DOPAMINE; FATIGUE SYNDROME, CHRONIC; GLUTATHIONE; LIPID PEROXIDATION; MALE; MAZE LEARNING; MEMORY; MICE; MOTOR ACTIVITY; NOREPINEPHRINE; OXIDATIVE STRESS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

MURINAE; MUS;

EID: 41949128168     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.02.011     Document Type: Article

References (59)

1. Akula K.K., Dhir A., Bishnoi M., and Kulkarni S.K. Effect of systemic administration of adenosine on brain adenosine levels in pentylenetetrazol-induced seizure threshold in mice. Neurosci Lett 425 (2007) 39-42
2. Anisman H., Hayley S., Turrin N., and Merali Z. Cytokines as a stressor: implications for depressive illness. Int J Neuropsychopharmacol. 5 (2002) 357-373
3. Berrocoso E., and Mica J.A. In vivo effect of venlafaxine on locus coeruleus neurons: role of opioid alpha(2)-adrenergic and 5-hydroxytryptamine(1A) receptors. J Pharmacol Exp Ther 322 (2007) 101-107
4. Beyer C.E., Boikess S., Luo B., and Dawson L.A. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. J Psychopharmacol 16 (2002) 297-304
5. Białyszewski A. The chronic fatigue syndrome. Psychiatr Pol 27 (1993) 601-611
6. Buchwald D., Pearlman T., Kith P., Katon W., and Schmaling K. Screening for psychiatric disorders in chronic fatigue and chronic fatigue syndrome. J Psychosom Res 42 (1997) 87-94
7. Cabib S., Zocchi A., and Puglisi-Allegra S. A comparison of the behavioral effects of minaprine amphetamine and stress. Psychopharmacology 121 (1995) 73-80
8. Capuron L., Welberg L., Heim C., Wagner D., Solomon L., Papanicolaou D.A., et al. Cognitive dysfunction relates to subjective report of mental fatigue in patients with chronic fatigue syndrome. Neuropsychopharmacology. 31 (2006) 1777-1784
9. Dhir A., and Kulkarni S.K. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion a dopamine reuptake inhibitor. Eur J Pharmacol 568 (2007) 177-185
10. Dhir A., and Kulkarni S.K. Involvement of l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in mice. Prog Neuro-psychopharmacol Biol Psychiatry 31 (2007) 921-925
11. 1) receptor modulation in the antidepressant action of venlafaxine. Neurosci Lett 420 (2007) 204-208
12. Dhir A., and Kulkarni S.K. Involvement of Dopamine (DA)/serotonin (5-HT)/Sigma (s) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride a D2/D3 dopamine receptor agonist. Brain Res Bull 74 (2007) 58-65
13. Dhir A., Naidu P.S., and Kulkarni S.K. Protective effect of cyclooxygenase-2 (COX-2) inhibitors but not non-selective cyclooxygenase (COX)-inhibitors on ethanol withdrawal-induced behavioural changes. Addict Biol 10 (2005) 329-335
14. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 82 (1959) 70-77
15. Gold PW, Licinio J, Wong ML, Chrousos GP. Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Stress: Basic Mechanisms and Clinical Implications 1995; 771: 716-729.
16. Goodnick P.J. Treatment of chronic fatigue syndrome with venlafaxine. Am J Psychiatry 153 (1996) 294
17. Gould G.G., Altamirano A.V., Javors M.A., and Frazer A. A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters. Biol Psychiatry 59 (2006) 408-414
18. Green L.C., Wagner D.A., and Glagowski J. Analysis of nitrate nitrite and [15N] nitrate in biological fluids. Anal Biochem 126 (1982) 131-138
19. Gutierrez M.A., Stimmel G.L., and Aiso J.Y. Venlafaxine: a 2003 update. Clin Ther 25 (2003) 2138-2154
20. Harvey B.H., Oosthuizen F., Brand L., Wegener G., and Stein D.J. Stress-restress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat hippocampus. Psychopharmacology (Berl) 175 (2004) 494-502
21. Hellerstein D.J., Batchelder S.T., Little S.A., Fedak M.J., Kreditor D., and Rosenthal J. Venlafaxine in the treatment of dysthymia: an open-label study. J Clin Psychiatry 60 (1999) 845-849
22. Imbe H., Iwai-Liao Y., and Senba E. Stress-induced hyperalgesia: animal models and putative mechanisms. Front Biosci 11 (2006) 2179-2192
23. Joca S.R., Ferreira F.R., and Guimaraes F.S. Modulation of stress consequences by hippocampal monoaminergic, glutamatergic and nitrergic neurotransmitter systems. Stress 10 (2007) 227-249
24. Jose L.M., Kalinin S., Richardson J.C., and Feinstein D.L. Neuroprotective actions of noradrenaline: effects on glutathione synthesis and activation of peroxisome proliferator activated receptor delta. J Neurochem 103 (2007) 2092-2101
25. Jose L.M., Madrigal, Feinstein D.L., and Dello Russo C. Norepinephrine protects cortical neurons against microglial-induced cell death. J Neurosci Res 81 (2005) 390-396
26. Kang J.Y., Kang H.J., Chung Y.K., Gwag B.J., and Noh J.S. 5-Hydroxytryptamine attenuates free radical injury in primary mouse cortical cultures. NeuroReport 12 (2001) 963-966
27. Katon W., and Walker E.A. The relationship of chronic fatigue to psychiatric illness in community, primary care and tertiary care sample. In: Bock G.R., and Whelan J. (Eds). Chronic Fatigue Syndrome (Ciba Foundation Symposium No. 173) (1993), John Wiley and Sons, Chiechester 193-211
28. Kennedy G., Spence V.A., McLaren M., Hill A., Underwood C., and Belch J.J. Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free Radic Biol Med 39 (2005) 584-589
29. Kipp D.E., and Rivers J.M. Uptake and release of adrenal ascorbic acid in the guinea pig after injection of ACTH. J Nutr 117 (1987) 1570-1575
30. Kulkarni S.K., and Dhir A. Effect of various classes of antidepressants in behavioral paradigms of despair. Prog Neuro-psychopharmacol Biol Psychiatry 31 (2007) 1248-1254
31. Kulkarni S.K., and Mehta A.K. Purine nucleoside-mediated immobility in mice reversal by antidepressants. Psychopharmacology (Berl) 85 (1985) 460-463
32. Kulkarni S.K., and Reddy D.S. Animal behavioral models for testing antianxiety agents. Meth Find Exp Clin Pharmacol 18 (1996) 219-230
33. Laney P.H., Levy J.A., and Kipp D.E. Plasma cortisol and adrenal ascorbic acid levels after ACTH treatment with a high intake of ascorbic acid in the guinea pig. Ann Nutr Metab 34 (1990) 85-92
34. Lorist M.M., Boksem M.A.S., and Ridderinkhof K.R. Impaired cognitive control and reduced cingulated activity during mental fatigue. Cogn Brain Res 24 (2005) 199-205
35. Lowry O.H., Rosenberg N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin-phenol reagent. J Biol Chem 193 (1951) 265-275
36. Maes M., Mihaylova I., Kubera M., and Bosmans E. Not in the mind but in the cell: increased production of cyclo-oxygenase-2 and inducible NO synthase in chronic fatigue syndrome. Neuro Endocrinol Lett 28 (2007) 463-469
37. McDonald E., Cope H., and David A. Cognitive impairment in patients with chronic fatigue: a preliminary study. J Neurol Neurosurg Psychiatry 56 (1993) 812-815
38. Miwa S., and Takikawa O. Chronic fatigue syndrome and neurotransmitters. Nippon Rinsho 65 (2007) 1005-1010
39. Parale M.P., and Kulkarni S.K. Clonidine-induced behavioural despair in mice Reversal by antidepressants. Psychopharmacology 89 (1986) 171-174
40. Quintero L., Moreno M., Avila C., Arcaya J., Maixner W., and Suarez-Roca H. Long-lasting delayed hyperalgesia after subchronic swim stress. Pharmacol Biochem Behav 67 (2000) 449-458
41. Reddy D.S., and Kulkarni S.K. Possible role of nitric oxide in the nootropic and antiamnesic effects of neurosteroids on aging and dizocilpine-induced learning impairment. Brain Res 799 (1998) 215-229
42. Reddy D.S., and Kulkarni S.K. Sex and estrous cycle-dependent changes in neurosteroid and benzodiazepine effects on food consumption and plus-maze learning behaviors in rats. Pharmacol Biochem Behav 62 (1999) 53-60
43. Redrobe J.P., Bourin M., Colombel M.C., and Baker G.B. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology 138 (1998) 1-8
44. Roe J.H., and Kuether C.A. The determination of ascorbic acid in whole blood and urine through the 2 4-dinitrophenyl hydrazine derivative of dehydro ascorbic acid. J Biol Chem 147 (1943) 399-407
45. Rönnbäck L., and Hansson E. On the potential role of glutamate transport in mental fatigue. J Neuroinflammation 1 (2004) 22
46. Roy-Byrne P., Afari N., Ashton S., Fischer M., Goldberg J., and Buchwald D. Chronic fatigue and anxiety/depression: a twin study. Br J Psychiatry 180 (2002) 29-34
47. Schmaling K.B., Fiedelak J.I., Katon W.J., Bader J.O., and Buchwald D.S. Prospective study of the prognosis of unexplained chronic fatigue in a clinic-based cohort. Psychosomatic Medicine 65 (2003) 1047-1054
48. Singh A., and Kulkarni S.K. Role of adenosine in drug-induced catatonia in mice. Indian J Exp Biol 40 (2002) 882-888
49. Singh A., Naidu P.S., Gupta S., and Kulkarni S.K. Effect of natural and synthetic antioxidants in a mouse model of chronic fatigue syndrome. J Med Food 5 (2002) 211-220
50. Strekalova T., Spanagel R., Dolgov O., and Bartsch D. Stress-induced hyperlocomotion as a confounding factor in anxiety and depression models in mice. Behav Pharmacol 16 (2005) 171-180
51. Terman M., Levine S.M., Terman J.S., and Doherty S. Chronic fatigue syndrome and seasonal affective disorder: comorbidity, diagnostic overlap, and implications for treatment. Am J Med 105 (1998) 115S-124S
52. Testa C.M., Sherer T.B., and Greenamyre J.T. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Molecular Brain Research 134 (2005) 109-118
53. Troadec J.D., Marien M., Darios F., Hartmann A., Ruberg M., Colpaert F., et al. Noradrenaline provides long-term protection to dopaminergic neurons by reducing oxidative stress. J Neurochem 79 (2001) 200-210
54. Vercoulen J.H., Swanink C.M., Zitman F.G., Vreden S.G., Hoofs M.P., Fennis J.F., et al. Randomised double-blind placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 347 (1996) 858-861
55. Wessely S., Chalder T., Hirsch S., Wallace P., and Wright D. Psychological symptoms somatic symptoms and psychiatric disorder in chronic fatigue and chronic fatigue syndrome: a prospective study in the primary care setting. Am J Psychiatry 153 (1996) 1050-1059
56. Wills E.D. Mechanism of lipid peroxide formation in animal tissues. Biochem. J. 99 (1966) 667-676
57. Xu Y., Ku B., Cui L., Li X., Barish P.A., Foster T.C., et al. Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. Brain Res. 1162 (2007) 9-18
58. Yokogawa F., Kiuchi Y., Ishikawa Y., Otsuka N., Masuda Y., Oguchi K., et al. An investigation of monoamine receptors involved in antinociceptive effects of antidepressants. Anesth Analg 95 (2002) 163-168
59. Zafir A., and Banu N. Antioxidant potential of fluoxetine in comparison to Curcuma longa in restraint-stressed rats. Eur J Pharmacol. 572 (2007) 23-31